Crescendo Bioscience, Inc.: Series C $31M

Posted in I - Series C, Q - 3Q11, R - WEST, X - Device (Diagnostic), X - RA, XX - CA

Crescendo Bioscience (San Francisco, CA) a commercial-stage molecular diagnostics company focused on quantitative biomarker tests for rheumatoid, closed a $31M Series C financing. Participants include Aeris Capital, Mohr Davidow Ventures and Kleiner Perkins Caufield & Byers.

ProtAb, Ltd.: Series A $1.5M

Posted in I - Series A, Q - 2Q10, R - INTERNATIONAL, X - Antibody, X - Inflammation, X - RA

ProtAb (Israel) a preclinical-stage biopharmaceutical company developing modulators of cytokine regulation and focused on a monoclonal antibody for the treatment rheumatoid arthritis, closed a $1.5M Series A financing. Participants include Pontifax Fund and Clal Biotechnology Industries.

Lycera Corp.: Series A $36M

Posted in I - Series A, Q - 2Q09, R - MID WEST, X - IBD, X - Lupus, X - RA, X - Therapeutic Platform, XX - MI

Lycera Corp (Ann Arbor, MA) a preclinical-stage biopharma company focused on small molecule immunomodulators for the treatment of rheumatoid arthritis, lupus erythematosis and inflammatory bowel disease, closed a $36M Series A financing. Participants include InterWest Partners, ARCH Venture Partners, Clarus Ventures and EDF Ventures.

AnaMar Medical, AB: Series B $9.3M

Posted in I - Series B, Q - 4Q08, R - INTERNATIONAL, X - RA

AnaMar Medical (Sweden) preclinical-stage developer of small molecule suppressor of inflammation and cartilage destruction in rheumatoid arthritis, closed a $9.3M Series B financing. Participants include Koncentra Holding and LinkMed.

Apitope International, Ltd.: Series A $12.8M

Posted in I - Series A, Q - 4Q08, R - INTERNATIONAL, X - Diagnostic, X - Multiple Sclerosis, X - RA, X - Vaccines

Apitope International (United Kingdome) developer of vaccines and diagnostics for autoimmune and allergic disease, closed a $12.8M Series A financing. Participants include Vesalius Biocapital, Vinnof and the University of Hasslet.

to top of page...